Pharma Resources (Shanghai) Co (SZSE:301230) Debt-to-Equity : 0.19 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharma Resources (Shanghai) Co Debt-to-Equity?

Pharma Resources (Shanghai) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥42.8 Mil. Pharma Resources (Shanghai) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥166.7 Mil. Pharma Resources (Shanghai) Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,103.4 Mil. Pharma Resources (Shanghai) Co's debt to equity for the quarter that ended in Mar. 2024 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharma Resources (Shanghai) Co's Debt-to-Equity or its related term are showing as below:

SZSE:301230' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.16 Max: 0.31
Current: 0.19

During the past 7 years, the highest Debt-to-Equity Ratio of Pharma Resources (Shanghai) Co was 0.31. The lowest was 0.07. And the median was 0.16.

SZSE:301230's Debt-to-Equity is ranked worse than
55.01% of 1058 companies
in the Biotechnology industry
Industry Median: 0.14 vs SZSE:301230: 0.19

Pharma Resources (Shanghai) Co Debt-to-Equity Historical Data

The historical data trend for Pharma Resources (Shanghai) Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Resources (Shanghai) Co Debt-to-Equity Chart

Pharma Resources (Shanghai) Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.13

0.18

0.31

0.09

0.19

Pharma Resources (Shanghai) Co Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.15	0.18	0.19	0.19

Competitive Comparison of Pharma Resources (Shanghai) Co's Debt-to-Equity

For the Biotechnology subindustry, Pharma Resources (Shanghai) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Resources (Shanghai) Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Resources (Shanghai) Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharma Resources (Shanghai) Co's Debt-to-Equity falls into.

Pharma Resources (Shanghai) Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharma Resources (Shanghai) Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(34.681	+	171.673)	/	1117.545
	=	0.18

Pharma Resources (Shanghai) Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(42.76	+	166.665)	/	1103.354
	=	0.19

Pharma Resources (Shanghai) Co (SZSE:301230) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharma Resources (Shanghai) Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharma Resources (Shanghai) Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Resources (Shanghai) Co (SZSE:301230) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Resources (Shanghai) Co Ltd (SZSE:301230) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 315, Qingda Road, Building 23, Pudong New Area, Shanghai, CHN, 201201

Website

http://www.pharmaresources.cn

Pharma Resources (Shanghai) Co Ltd is engaged in the drug discovery, research and development of pharmaceutical processes, and commercial production of API intermediates.

Pharma Resources (Shanghai) Co (SZSE:301230) Headlines

No Headlines